未经治疗的局限性（T0至3NxM0期，1至3级）前列腺癌中前列腺特异性抗原的系列测量与疾病进展
Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate.
作者信息
Bangma C H, Schröder F H
机构信息
Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands.
出版信息
J Urol. 1995 Oct;154(4):1403-6.
PURPOSE
The contribution of serial prostate specific antigen (PSA) determinations was studied to obtain better understanding of the natural history of clinically confined prostate carcinoma.
MATERIALS AND METHODS
Serial PSA determinations in 29 patients with untreated confined prostate carcinoma were correlated to the clinical course for a mean of 39 months.
RESULTS
Disease progressed locally in 13 patients after a mean of 31 months. Metastatic progression was not observed. Neither grade, stage, PSA changes nor initial PSA showed significant differences with respect to interval of progression between patients with and without progression.
CONCLUSIONS
PSA does not parallel clinical progression in patients selected for watchful waiting.
目的
研究系列前列腺特异性抗原（PSA）检测，以更好地了解临床局限性前列腺癌的自然病程。
材料与方法
对29例未经治疗的局限性前列腺癌患者进行系列PSA检测，并将其与平均39个月的临床病程相关联。
结果
13例患者在平均31个月后出现局部疾病进展。未观察到转移进展。无论分级、分期、PSA变化还是初始PSA，进展患者与未进展患者之间在进展间隔方面均未显示出显著差异。
结论
对于选择观察等待的患者，PSA与临床进展不平行。
Zotero 插件